Andrew Gerry
About Andrew Gerry
Andrew Gerry serves as the Vice President of Preclinical Research at Adaptimmune, a position he has held since 2017. He has extensive experience in the field, having worked in various roles at Adaptimmune since 2007 and earned a PhD in Cell and Molecular Biology from the University of Reading.
Work at Adaptimmune
Andrew Gerry has held multiple positions at Adaptimmune since joining the company in 2007. He currently serves as the Vice President of Preclinical Research, a role he has occupied since 2017. Prior to this, he was the Director of Preclinical Research from 2016 to 2017. He also worked as the Head of Pipeline Preclinical Cell Testing from 2014 to 2015. Earlier in his career at Adaptimmune, he served as a Senior Scientist from 2007 to 2011 and as a Group Leader from 2012 to 2013.
Education and Expertise
Andrew Gerry earned his Doctor of Philosophy (PhD) in Cell and Molecular Biology from the University of Reading. His academic background has provided him with a strong foundation in scientific research, particularly in the fields relevant to preclinical studies and cell testing.
Background
Before joining Adaptimmune, Andrew Gerry worked as a Postdoctoral Scientist at the University of Reading from 2004 to 2007. This role contributed to his expertise in scientific research and development, particularly in the context of cell and molecular biology.
Career Progression
Andrew Gerry's career at Adaptimmune reflects a steady progression through various roles with increasing responsibility. Starting as a Senior Scientist, he advanced to Group Leader, then to Head of Pipeline Preclinical Cell Testing, and subsequently to Director of Preclinical Research before assuming his current role as Vice President.